Fourth -Quarter 2025 Earnings Baxter International Inc. February 12, 2026 1 Forward-Looking Statements To supplement Baxter's consolidated financial statements presented on a U.S. GAAP basis, the company discloses certain non-GAAP financial measures. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. A reconciliation of the non-GAAP financial measures included in this document to the corresponding U.S. GAAP measures follows in the sect ...

- Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country -TUCSON, Ariz., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that University of California, San Francisco (UCSF) Health ...

Core Insights - Profound Medical Corp. has been awarded the 2025/2026 Mount Logan Award for its achievements in interventional MRI procedures, particularly for the TULSA Procedure [1][2] Company Achievements - The company has treated its 4,000th TULSA Procedure patient and secured new U.S. reimbursement codes from Medicare, enhancing its market position [2] - Profound Medical has established strategic partnerships to expand global patient access to its technologies [2] - The TULSA Procedure is a significant advancement in prostate care, utilizing robotically controlled ultrasound and real-time MRI thermography for precise treatment [2][5] Technology Overview - The TULSA Procedure employs a unique method of delivering ultrasound from within the urethra to heat prostate tissue to 'kill temperature' (55-57°C), minimizing side effects and ensuring no procedural blood loss [2][5] - The procedure is incision-free, requires no overnight hospital stay, and allows for a quick recovery, making it a compelling option for patients [5] Market Position and Future Plans - Currently, there is only one TULSA-PRO system installed in Canada, but the company aims to increase installations following the regain of exclusive distribution rights in the country [3] - Profound Medical is deploying a direct sales team in North America and partnering with strategic distribution partners to enhance its global reach [3] Additional Products - Profound Medical is also commercializing Sonalleve, a therapeutic platform approved for treating uterine fibroids and other conditions, with potential applications in non-invasive cancer treatments [6]

Core Viewpoint - EDAP TMS S.A. has appointed David Horn to its Board of Directors, effective February 11, 2026, enhancing the board's expertise in strategic growth and transformation [1][2]. Group 1: Appointment Details - David Horn brings extensive experience in capital markets and the medical device industry, having served as President and CFO of Seer, Inc. since 2023 and previously at Morgan Stanley for over 20 years [3]. - Horn will be a member of the Audit Committee and Nominations Committee, contributing to strategic planning and execution [2][3]. Group 2: Company Leadership and Strategy - The Chairman of the Board, Lance Willsey, expressed confidence in Horn's ability to support EDAP's growth strategy and enhance shareholder value [3]. - Horn emphasized the importance of EDAP's innovation in focal therapy technology and its potential to expand clinical indications [4]. Group 3: Board Changes - Glen French has stepped down from the Board of Directors effective February 10, 2026, with appreciation expressed for his contributions [4][5].

Core Viewpoint - Catheter Precision, Inc. has terminated its at-the-market equity offering program and secured a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth [1][3]. Group 1: Financial Position and Strategy - The termination of the ATM equity offering program is aimed at strengthening the company's balance sheet and aligning with long-term institutional capital for value creation [1][3]. - The strategic financing enhances institutional investor confidence in the company's strategy and eliminates legacy financing overhang [3][7]. - The company has converted short-term notes to long-term by extending maturities to two and three years, significantly strengthening its balance sheet and liquidity [7]. Group 2: Growth Initiatives - The strategic institutional investment provides financial flexibility to advance key growth initiatives and scale multiple business opportunities [4][8]. - The company aims to expand its market presence and execution capabilities through this new capital [8].

Investor Presentation February 12, 2026 CONFIDENTIAL – DO NOT DISTRIBUTE Safe harbor statement This presentation contains "forward-looking statements" that are based on our management's beliefs and assumptions and on information available to management as of February 12, 2026. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include inform ...

Investor Presentation Carl Zeiss Meditec Group 00.40 15.50 08.92 07.40 Investor Relations February 2026 15.50 00.40 15.50 00.00 06.60 05.00 08.70 Agenda | 01 | At a Glance | | --- | --- | | 02 | Strategy | | 03 | Facts and Figures | | 04 | Outlook | | 05 | Appendix | Carl Zeiss Meditec 2 00.40 00.40 15.50 08.92 07.40 00.00 06.60 05.00 08.70 Our markets benefit from structural tailwinds ZEISS ophthalmic surgical solutions cover a patient's entire ocular lifecycle Ametropia (Hyperopia, Myopia, Astigmatism) Pr ...

Core Viewpoint - Inspire Medical Systems is navigating reimbursement and coding uncertainties related to its Inspire 5 system, which could significantly impact professional fees and revenue outlook for 2026 [3][4][16]. Financial Performance - Q4 2025 revenue was $269 million, representing a 12% increase, while full-year revenue reached $912 million, up 14% [5][11]. - The company reported a net income per diluted share of $4.66 for Q4 and $4.89 for the full year, both showing substantial increases from the previous year [15]. - Cash and investments totaled $405 million, with share buybacks amounting to $175 million for the full year [5][15]. Coding and Reimbursement - The coding for the Inspire 5 procedure is expected to transition to CPT 64582 with a -52 modifier, potentially reducing professional fees by 10% to 50% [3][6][17]. - Inspire has revised its 2026 revenue guidance to a range of $950 million to $1.0 billion, reflecting the impact of coding changes and physician reimbursement uncertainties [13][16]. Operational Updates - Over 90% of centers are now implanting the Inspire 5 system, with significant progress in the U.S. launch [14]. - The company is nearing completion of manufacturing for Inspire 4 systems and expects stable inventory through 2026 [9]. Clinical and R&D Developments - Inspire 5 has shown promising clinical results, with a 79.5% responder rate in a Singapore study, compared to 66% in the STAR Phase III trial [8]. - The company has received FDA approval for 3 Tesla MRI compatibility and is advancing R&D towards Inspire 6, which will include enhanced features for sleep detection and therapy activation [10]. Marketing and Cost Management - Inspire is focusing on cost discipline and flexibility in spending, with marketing efforts expected to remain flat to slightly up, emphasizing social media and digital channels [18].

Group 1 - The overall market size of surgical robots in China is expected to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, with a CAGR of approximately 34% [1] - The market for laparoscopic surgical robots is projected to have a CAGR of about 29% from 2024 to 2032, driven by the release of pricing directories and increased penetration rates [1] - The orthopedic surgical robot market is anticipated to grow at a CAGR of around 41% during the same period, supported by the implementation of pricing directories and increasing hospital admissions [1] Group 2 - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2] - The global market for leading surgical robot companies has surpassed 1 trillion RMB in market value, with significant growth potential in penetration rates and market size [2] - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2] Group 3 - Related Hong Kong stocks in the surgical robot sector include Precision Surgery-B (02675), MicroPort Scientific-B (02252), and Kangji Medical (09997) [3]

Core Viewpoint - Zimmer Biomet Holdings, Inc. has demonstrated strong financial performance in the fourth quarter of 2025 and for the full year, highlighting its strategic focus on growth and shareholder returns. Financial Performance - In Q4 2025, Zimmer Biomet reported net sales of $2.244 billion, a 10.9% increase year-over-year [2] - The company's net earnings for Q4 were $139.3 million, with a gross profit of $785.4 million [2] - For the full year, net sales reached $8.232 billion, reflecting a 7.2% increase from the previous year [3] - Operating cash flow for the year was $1.697 billion, and free cash flow was $1.172 billion [3] Earnings Per Share - Diluted earnings per share decreased by 41.7% to $0.70 in Q4, while adjusted diluted earnings per share increased by 4.8% to $2.42, exceeding estimates of $2.38 [2] Strategic Initiatives - The company has implemented a direct and specialized sales organization in the U.S. to drive long-term growth [2] - A new stock repurchase authorization of up to $1.5 billion has been approved, effective from February 9, 2026, with no expiration date, indicating a commitment to returning capital to shareholders [3] Acquisitions - The acquisition of Paragon 28, Inc. in April 2025 has been excluded from organic constant currency sales calculations to provide a clearer performance picture [4] - The company remains focused on delivering EPS and free cash flow growth, as emphasized by its leadership [4]